Which phase 3 Alzheimer's trials posted results with a primary completion since 2024?

Answered byClinicalTrials.gov API: trial search & NCT dossier

Price$0.004 per trial (HTTP API)

StatusOn the HTTP API

ClinicalTrials.gov lists phase 3 Alzheimer's trials that have posted results and reached primary completion since 2024. Each row has the NCT number, title, status, sponsor, enrollment, start and primary completion dates, countries and primary outcomes, with a link to the trial record.

Tool input

{
  "condition": "Alzheimer disease",
  "phase": [
    "PHASE3"
  ],
  "hasResults": true,
  "primaryCompletionFrom": "2024-01-01",
  "maxResults": 20
}

Ask it from an AI agent (MCP)

Add the Apify MCP server with this tool to your MCP client (Claude, Cursor, VS Code, ...); it signs you in with OAuth or Authorization: Bearer <APIFY_TOKEN>. It works once the Actor is listed on the Apify Store; until then use the HTTP API or the remote MCP server at https://api.boscolabs.dev/mcp.

https://mcp.apify.com?tools=bosco_labs/clinical-trials

Then ask:

Use the bosco_labs/clinical-trials tool to answer: Which phase 3 Alzheimer's trials posted results with a primary completion since 2024?

Call the Apify API

Runs the Actor and returns the rows in one request, billed to your Apify account ($0.004 per trial (HTTP API)). It works once the Actor is listed on the Apify Store; until then use the HTTP API or the remote MCP server at https://api.boscolabs.dev/mcp.

curl https://api.apify.com/v2/acts/bosco_labs~clinical-trials/run-sync-get-dataset-items \
  -H "Authorization: Bearer $APIFY_TOKEN" \
  -H "Content-Type: application/json" \
  -d '{"condition": "Alzheimer disease", "phase": ["PHASE3"], "hasResults": true, "primaryCompletionFrom": "2024-01-01", "maxResults": 20}'

Call the Bosco Labs HTTP API

Bosco Labs HTTP API (beta): same input and rows, $0.004 per trial from prepaid credits. Get a key with a $0.50 free trial, or send the same call without a key and pay per call in USDC via x402 (no account).

curl https://api.boscolabs.dev/v1/clinical-trials \
  -H "Authorization: Bearer $BOSCO_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"condition": "Alzheimer disease", "phase": ["PHASE3"], "hasResults": true, "primaryCompletionFrom": "2024-01-01", "maxResults": 20}'

Example output

Snapshot taken 2026-11-06, source links in each row. First 1 of 5 rows (snapshot runs stop at 5 rows); long values shortened.

[
  {
    "nct_id": "NCT05891496",
    "title": "A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's Disease",
    "acronym": null,
    "status": "COMPLETED",
    "phases": [
      "PHASE3"
    ],
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Alzheimers Disease"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Semaglutide"
      },
      {
        "type": "DRUG",
        "name": "Placebo"
      }
    ],
    "sponsor": "Novo Nordisk A/S",
    "sponsor_class": "INDUSTRY",
    "collaborators": [],
    "enrollment_count": 23,
    "enrollment_type": "ACTUAL",
    "start_date": "2023-06-20",
    "start_date_type": "ACTUAL",
    "primary_completion_date": "2024-08-19",
    "primary_completion_date_type": "ACTUAL",
    "completion_date": "2025-09-08",
    "completion_date_type": "ACTUAL",
    "last_update_posted": "2026-08-18",
    "countries": [
      "Canada",
      "Denmark",
      "Italy",
      "... 3 more"
    ],
    "site_count": 12,
    "primary_outcomes": [
      {
        "measure": "Change in Gene Expression Assessed by Single-cell Ribonucleic Acid Sequencing (scRNAseq) (Cells in Cerebrospinal Fluid [CSF])",
        "time_frame": "Baseline (week 0), week 12"
      },
      {
        "measure": "Change in Gene Expression Assessed by scRNAseq (Cells in Blood)",
        "time_frame": "Baseline (week 0), week 12"
      }
    ],
    "primary_outcomes_total": 2,
    "has_results": true,
    "results_first_posted": "2026-02-24",
    "brief_summary": "The study is being conducted to understand how the medicine, semaglutide, affects the immune system and other biological processes in people with Alzheimer's...",
    "eligibility": null,
    "arms": null,
    "secondary_outcomes": null,
    "sites": null,
    "source_url": "https://clinicaltrials.gov/study/NCT05891496",
    "...": "4 more fields"
  }
]

Call it on the HTTP API →All fields and limits